Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TapImmune, a biotechnology company specialising in the development of immunotherapeutics for the treatment of cancer and infectious disease, has signed a licensing option agreement with Mayo Clinic, for the clinical development of a breast cancer vaccine technology.
Subscribe to our email newsletter
The option to license the breast cancer vaccine technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune.
Reportedly, upon IND approval TapImmune and Mayo Clinic will execute a sponsored research agreement.
Mayo Clinic will conduct a Phase I clinical trial in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer).
Keith Knutson, of Mayo Clinic, will serve as principal investigator.
Glynn Wilson, chairman and CEO of TapImmune, said: “We believe that this technology offers a number of advantages in the development of a breast cancer vaccine for a broad patient population. The option to license this technology from Mayo Clinic offers us potential to enhance our cancer vaccine portfolio and clinical research programs.”